[go: up one dir, main page]

ZA87793B - Formulations suitable for the stabilisation of alpha-interferon - Google Patents

Formulations suitable for the stabilisation of alpha-interferon

Info

Publication number
ZA87793B
ZA87793B ZA87793A ZA87793A ZA87793B ZA 87793 B ZA87793 B ZA 87793B ZA 87793 A ZA87793 A ZA 87793A ZA 87793 A ZA87793 A ZA 87793A ZA 87793 B ZA87793 B ZA 87793B
Authority
ZA
South Africa
Prior art keywords
active ingredient
alpha
stabilisation
interferon
formulations suitable
Prior art date
Application number
ZA87793A
Inventor
Helmut Franz
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of ZA87793B publication Critical patent/ZA87793B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The pharmaceutical forms are intended for topical administration and employ as vehicle for and stabiliser of the active ingredient a composition which specifically confers special stability on the active ingredient IFN alpha. The forms are essentially composed of hydroxyethylcellulose and gelatin and preferably contain highly purified IFN alpha which has been prepared by DNA recombination as active ingredient.
ZA87793A 1986-02-05 1987-02-04 Formulations suitable for the stabilisation of alpha-interferon ZA87793B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863603444 DE3603444A1 (en) 1986-02-05 1986-02-05 PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA

Publications (1)

Publication Number Publication Date
ZA87793B true ZA87793B (en) 1988-10-26

Family

ID=6293372

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA87793A ZA87793B (en) 1986-02-05 1987-02-04 Formulations suitable for the stabilisation of alpha-interferon

Country Status (20)

Country Link
EP (1) EP0231816B1 (en)
JP (1) JPS62209024A (en)
KR (1) KR870007698A (en)
AT (1) ATE63823T1 (en)
AU (1) AU601712B2 (en)
CA (1) CA1295242C (en)
DD (1) DD284602A5 (en)
DE (2) DE3603444A1 (en)
DK (1) DK164202C (en)
ES (1) ES2028796T3 (en)
FI (1) FI86144C (en)
GR (1) GR3002270T3 (en)
HU (1) HU196560B (en)
IE (1) IE59697B1 (en)
IL (1) IL81472A0 (en)
NO (1) NO169638C (en)
NZ (1) NZ219169A (en)
PH (1) PH24377A (en)
PT (1) PT84243B (en)
ZA (1) ZA87793B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275804A (en) * 1986-02-25 1994-01-04 E. B. Michaels Research Associates, Inc. Process and composition for oral hygiene
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3731255A1 (en) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3803312A1 (en) * 1988-02-04 1989-08-10 Gerd Prof Dr Med Gross Use of an interferon-containing gel
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
ATE110571T1 (en) * 1988-05-06 1994-09-15 Toray Industries STABLE INTERFERON BETA COMPOSITION.
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
US5244652A (en) * 1991-03-22 1993-09-14 E. B. Michaels Research Associates, Inc. Viscous surface active composition
WO1993006856A1 (en) * 1991-10-11 1993-04-15 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
FI106465B (en) * 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Process for the preparation of virus-safe pharmaceutical compositions
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
JP4536194B2 (en) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 Stable injectable formulation
IL151649A0 (en) * 2000-03-07 2003-04-10 Rush Presbyterian St Luke Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
US20050013791A1 (en) * 2001-11-02 2005-01-20 Kazuo Shinmura Cytokine-inducing material and cytokine-inducing instrument
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
MX347440B (en) * 2009-05-29 2017-04-26 Filligent Ltd Composition for use in decreasing the transmission of human pathogens.
RU2431489C1 (en) * 2010-05-25 2011-10-20 Федеральное государственное учреждение "Российский научный центр рентгенорадиологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "РНЦРР Росмедтехнологий") Method of treating chronic inflammatory bowel diseases
AU2013225716B2 (en) * 2012-03-01 2017-10-12 Xequel Bio, Inc. Topical gels containing alpha connexin C-terminal (ACT) peptides
JP6081156B2 (en) * 2012-11-15 2017-02-15 アルケア株式会社 Hydrogel
DE102012222365A1 (en) 2012-12-05 2014-06-05 Aesculap Ag Composition for use in the prophylaxis of post-surgical adhesions
US20160120946A1 (en) * 2013-06-09 2016-05-05 Efranat Ltd. Compositions comprising gc-macrophage activating factor and uses thereof
AU2017397235B2 (en) 2017-01-31 2023-09-21 Kimberly-Clark Worldwide, Inc. Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same
US12138293B2 (en) 2020-10-22 2024-11-12 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
JPS6061535A (en) * 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト Pharmaceutical composition
JPS6069037A (en) * 1983-09-26 1985-04-19 Sunstar Inc External preparation for erythematosus
DE3484951D1 (en) * 1983-10-14 1991-09-26 Sumitomo Pharma EXTENDED PREPARATIONS WITH DELAYED DELIVERY.
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS60260523A (en) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd Freeze-dried pharmaceutical composition of interferon

Also Published As

Publication number Publication date
HUT43494A (en) 1987-11-30
NZ219169A (en) 1990-04-26
DE3770280D1 (en) 1991-07-04
GR3002270T3 (en) 1992-12-30
ES2028796T3 (en) 1992-07-16
NO169638C (en) 1992-07-22
PT84243A (en) 1987-03-01
JPS62209024A (en) 1987-09-14
PT84243B (en) 1989-09-14
HU196560B (en) 1988-12-28
EP0231816A3 (en) 1987-09-23
ATE63823T1 (en) 1991-06-15
DK164202C (en) 1992-10-19
AU6829287A (en) 1987-08-06
FI86144B (en) 1992-04-15
DE3603444A1 (en) 1987-08-06
EP0231816B1 (en) 1991-05-29
IL81472A0 (en) 1987-09-16
IE59697B1 (en) 1994-03-23
DK58387A (en) 1987-08-06
CA1295242C (en) 1992-02-04
NO870441D0 (en) 1987-02-04
FI870457A0 (en) 1987-02-03
NO169638B (en) 1992-04-13
DD284602A5 (en) 1990-11-21
DK58387D0 (en) 1987-02-04
NO870441L (en) 1987-08-06
IE870295L (en) 1987-08-05
AU601712B2 (en) 1990-09-20
PH24377A (en) 1990-06-13
EP0231816A2 (en) 1987-08-12
DK164202B (en) 1992-05-25
KR870007698A (en) 1987-09-21
FI86144C (en) 1992-07-27
FI870457L (en) 1987-08-06

Similar Documents

Publication Publication Date Title
ZA87793B (en) Formulations suitable for the stabilisation of alpha-interferon
CA2058428A1 (en) Analgesic formulations
ES2009216A6 (en) IL-1alpha derivatives and drugs.
AU7076887A (en) Nasal administration of drugs
PT779805E (en) SUSTAINED LIBERTACATION OF PEPTIDES OF PHARMACEUTICAL COMPOSITIONS
DK0395329T4 (en) Composition in the form of a foam containing 5-aminosalicylic acid for intrarectal administration
IL108071A0 (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines their preparation and pharmaceutical compositions containing them
IL79816A0 (en) Pharmaceutical composition comprising a drug-polymer matrix
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
DK305087A (en) BUPRENORPHIC CONTAINED PHARMACEUTICAL SUPPLY
IL78604A (en) Process for the preparation of homogeneous,pure alpha-interferon,alpha-interferon produced thereby and pharmaceutical compositions containing it
GB2021409A (en) Pharmaceutical composition
AU581855B2 (en) 1-(4'-alkylsulphonylphenyl)-2-amino-1, 3-propanediol n-substituted derivatives
IE56229B1 (en) 2-piperazinyl-or-homopiperazinyl-quinazoline derivatives their production and pharmaceutical compositions containing them
DK0524696T3 (en) Oral preparations containing dapiprazole
AU581856B2 (en) 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives
ES2054029T3 (en) FLECAINIDE ACETATE FORMULATION WITH CONTROLLED RELEASE.
IL106289A0 (en) Phospholipid derivatives, their preparation and pharmaceutical compositions containing them
GB1351437A (en) N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity
EP0355899A3 (en) Nucleotide derivatives
ES2091571T3 (en) NEW ACTIVE PEPTIDIC DERIVATIVES IN THE CELL ADHESION PROCESSES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ATE102934T1 (en) FLUORINATED FLAVONACETIC ACID.
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
ES2135424T3 (en) ORAL COMPOSITION BASED ON IBUPROFEN.
IT1241459B (en) Pharmaceutical compositions for the rectal administration of calcitonin.